SHANGHAI – Any discussion of innovative biologics at the recent Chinabio Forum inevitably brought up biosimilars; it is difficult to have one without the other, probably because local companies of any size or staying power developing biologics take that twin strategy, filling their pipelines with biosimilars, whether me-too or bio-better, along with a smattering of novel candidates.